Selecting Optimal First-line Antiretroviral Therapy for Rapid Start

Gain expert perspectives on the available safety and efficacy data on recommended regimens for rapid start in newly diagnosed patients with HIV.

Share

Program Content

No activities added yet

No activities added yet

Supporters

Supported by an educational grant from

Janssen Therapeutics Division of Janssen Products